Efficacy and safety of eplivanserin 5mg/day on sleep maintenance insomnia: a 12-week, multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension with eplivanserin for a 40-week period.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Eplivanserin (Primary)
- Indications Sleep maintenance insomnia
- Focus Registrational; Therapeutic Use
- Acronyms EPLILONG
- Sponsors Sanofi
- 25 Mar 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 24 Mar 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 24 Mar 2009 Planned number of patients changed from 1120 to 1155 as reported by ClinicalTrials.gov.